Ideaya Biosciences Inc

NASDAQ:IDYA  
13.59
+0.23 (+1.72%)
Earnings Announcements

IDEAYA Biosciences Inc Reports Third Quarter 2020 Financial Results And Provides Business Update

Published: 11/12/2020 11:19 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update.
Ideaya Biosciences Inc - Parg and Pol Theta Programs Targeting Development Candidate in 2021.
Ideaya Biosciences Inc - Anticipate Interim Data in 2021 for Ide196/binimetinib Combination Arm.
Ideaya Biosciences Inc - Anticipate Interim Data in 2021 for Ide196 Monotherapy Arm of Phase 1/2 Gnaq/11 Basket Trial.
Ideaya Biosciences Inc Qtrly Total Revenue $9mln.
Ideaya Biosciences Inc Qtrly Loss per Share $0.17.
Revenue is expected to be $9.07 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $10.5 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.